

Curriculum Vitae

Name : Myeong-Cherl Kook, M.D. & Ph.D.

Current Address : Department of Pathology and Center for Gastric Cancer
National Cancer Center Hospital
111 Jungbalsan-ro, Ilsandong-gu, Goyang-si
Gyeonggi-do 410-769, Republic of Korea
Tel) +82-31-920-1745
Fax) +82-31-920-1369



Academic Career:

Jul. 2004 - Present : Staff Pathologist
Department of Pathology and Center for Gastric Cancer
National Cancer Center Hospital

Mar. 2003 – Jun. 2004 : Research fellow
Department of Pathology
Seoul National University College of Medicine

Sep. 2002 - Feb. 2003 : Assistant Professor
Department of Pathology
Cheju National University College of Medicine

May. 2000 - Aug. 2002 : Instructor
Department of Pathology
Cheju National University College of Medicine

May. 1998 - Apr. 2000 : Medical Investigator
Department of Forensic Medicine
Institute of Scientific Investigation,
Ministry of National Defense

Apr. 1997 – Apr. 1998 : Medical officer
Army

Mar. 1995 - Aug. 2001 : Doctor of Philosophy
Department of Pathology
Seoul National University College of Medicine

Mar. 1993 - Feb. 1995 : Master of Medical Science
Department of Pathology
Seoul National University College of Medicine

Mar. 1993 - Feb. 1997 : Residentsip
Department of Pathology
Seoul National University Hospital
Mar. 1992 - Feb. 1993 : Internship
Seoul National University Hospital
Mar. 1988 - Feb. 1992 : M.D. (ID No.: 47570)
Seoul National University College of Medicine

MS degree

Relationship between morphologic findings and renal functions observed in renal amyloidosis- 1995. 2.

Doctor of Philosophy

Expression pattern of SY antigen, a novel transmembrane protein of mouse, in various developmental stages of mouse fetuses. 2001.8.

Organizations:

The Korean Society of Pathologists, regular member
Gastrointestinal Pathology Study Group, regular member
The Korean Gastric Cancer Association, regular member

Publication list:

Helicobacter pylori Therapy for the Prevention of Metachronous Gastric Cancer. N Engl J Med. 378(12):1085-1095. 2018

Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis. Lancet Oncol. 19(5):629-638. 2018

Factors to improve the interobserver agreement for gastric atrophy and intestinal metaplasia: consensus of definition and criteria. Histopathology. 72(5):838-845. 2018

Sporadic Early-Onset Diffuse Gastric Cancers Have High Frequency of Somatic CDH1 Alterations, but Low Frequency of Somatic RHOA Mutations Compared With Late-Onset Cancers. Gastroenterology. 153(2):536-549. 2017

Nomogram Incorporating CD44v6 and Clinicopathological Factors to Predict Lymph Node Metastasis for Early Gastric Cancer PLoS One. 11:e0159424 2016

Practical intraoperative pathologic evaluation of sentinel lymph nodes during sentinel node navigation surgery in gastric cancer patients - Proposal of the pathologic protocol for the upcoming SENORITA trial Surg Oncol.25:139-46 2016

Optimal submucosal invasion of early gastric cancer for endoscopic resection Ann Surg Oncol. 22:1806-12 2015

Risk of Lymph Node Metastasis in Differentiated Type Mucosal Early Gastric Cancer Mixed with Minor Undifferentiated Type Histology Ann Surg Oncol. 22:1813-19. 2015

Peroxisome proliferator-activated receptor γ upregulates galectin-9 and predicts prognosis

in intestinal-type gastric cancer *Int J Cancer*. 136:810-20. 2015

HNF4a is a therapeutic target that links AMPK to WNT signaling in early-stage gastric cancer *Gut.Epub*. 2014